Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SNC115 in Recurrent/Refractory SCLC and Lung LCNEC
NCT06384482Phase 1Recruiting
- Sponsor
- Simnova Biotherapeutics
- Start
- Apr 2024
- Primary completion
- Apr 2025
- Modality
- CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SNC-115 in small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC), sponsored by Simnova Biotherapeutics. Primary endpoints: Safety of SNC115 Injection (Incidence and severity of AEs and SAEs) and Safety of SNC115 Injection (Occurrence rate of DLT). Started Apr 2024; status: recruiting.
02
Drugs
SNC-115
03
Conditions
small cell lung cancer (SCLC)large cell neuroendocrine carcinoma (LCNEC)
Beyond the preview
Go deeper on NCT06384482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06384482.